Selvita Establishes its UK Subsidiary in Cambridge
News May 07, 2015
Selvita is opening its first office in the United Kingdom. The office is based in Cambridge, considered to be one of the most significant biotechnology clusters in the world. The new office will be responsible for supporting the ongoing projects for the customers from the UK and Northern Ireland, as well as seeking new collaboration opportunities in the area of integrated drug discovery services with pharma and biotech companies in the region. Selvita Ltd. will be focused on supporting and developing business relationships with local partners whereas Selvita’s laboratories remain in Krakow, Poland.
Selvita is one of the largest drug discovery companies in Europe. It currently employs more than 230 professionals, mainly chemists and molecular biologists, 80 of whom have a PhD degree. The company offers integrated drug discovery services, medicinal chemistry, custom synthesis, in vitro biology services, protein production and analytical services.
Selvita also conducts its own small-molecule research programs in oncology. Selvita’s client base includes many medium and large pharmaceutical and biotechnology companies from the USA, Western and Central Europe, Israel, Japan and Brazil. Selvita is listed on the Warsaw Stock Exchange.
“Selvita laboratories are currently located at 20 000 sq. ft. in a modern life science park in Krakow, Poland. We continuously invest in top-class equipment and employ highly skilled professionals with experience from some of the most renowned pharmaceutical companies in Western Europe and the US. This sets us among the biggest and the most innovative contract research providers in Central and Eastern Europe. Our location in Poland allows us to offer our clients significant cost efficiencies compared to other geographies. We decided to establish direct presence in the UK, in order to be closer to our business partners located in the UK.” - says Dr Milosz Gruca, Chief Executive Officer at Selvita UK.
The United Kingdom is the third largest global R&D market. Biotechnology clusters are springing up around the country. Drug innovators seek out the high quality contract service providers mainly because it translates to accessing additional skillsets and reduced internal costs. Selvita, whose mission is to help their partners to maximize productivity and lower costs of product development, is glad to become a part of this environment.
“I am excited that Selvita is establishing its presence in Cambridge - home to the leading scientific organizations. This step will allow us to become more visible on the local market and remain at full disposal of our UK-based customers. I strongly believe that Selvita can become a valuable partner for many leading pharmaceutical and biotechnology companies in the UK and Northern Ireland” - says Alicja Malysiak, Vice President of Sales at Selvita UK.
Existing 20-year-old Multiple Sclerosis Drug Effective Against Multi-resistant BacteriaNews
A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.READ MORE
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE